Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Current Deferred Revenue (2016 - 2018)

Alaunos Therapeutics (TCRT) has disclosed Current Deferred Revenue for 8 consecutive years, with $13000.0 as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Current Deferred Revenue fell 90.78% year-over-year to $13000.0, compared with a TTM value of $13000.0 through Dec 2018, down 90.78%, and an annual FY2018 reading of $13000.0, down 90.78% over the prior year.
  • Current Deferred Revenue was $13000.0 for Q4 2018 at Alaunos Therapeutics, down from $49.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $49.5 million in Q3 2018 and bottomed at $13000.0 in Q4 2018.
  • Average Current Deferred Revenue over 5 years is $3.9 million, with a median of $262000.0 recorded in 2014.
  • The sharpest move saw Current Deferred Revenue surged 3509.6% in 2017, then tumbled 99.01% in 2018.
  • Year by year, Current Deferred Revenue stood at $280000.0 in 2014, then grew by 24.29% to $348000.0 in 2015, then tumbled by 55.46% to $155000.0 in 2016, then fell by 9.03% to $141000.0 in 2017, then plummeted by 90.78% to $13000.0 in 2018.
  • Business Quant data shows Current Deferred Revenue for TCRT at $13000.0 in Q4 2018, $49.5 million in Q3 2018, and $63000.0 in Q2 2018.